Seres Therapeutics (MCRB) shares were down almost 14% in recent Thursday trading after Chardan downgraded the biotechnology company's stock to neutral from buy and cut its target price to $6 per share from $25.
Trading volume stood at over 164,000 shares compared with a daily volume of 73,257.
Price: 7.14, Change: -1.15, Percent Change: -13.87
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.